The Vaccines and Related Biological Products Advisory Committee is likely to recommend today that FDA approve a COVID-19 vaccine developed by Pfizer and BioNTech.

On November 10, FDA issued an emergency use authorization (EUA) to Eli Lilly for the investigational monoclonal antibody therapy bamlanivimab to treat mild to moderate COVID-19 in adult and pediatric patients.